FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia
Welcome,         Profile    Billing    Logout  
 0 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tryakin, Alexey
CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting
3
355
RoW
Cetuximab, panitumumab
City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
12/26
12/27
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
GENCONCOR-1, NCT06449989: Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Recruiting
N/A
30
RoW
Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI
Blokhin's Russian Cancer Research Center
Colorectal Cancer Metastatic, Brain Metastases, Adult, Ras (KRAS or NRAS) Gene Mutation, BRAF Gene Mutation, HER2 Gene Mutation, MSI
04/25
04/25
Ganshina, Inna
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
Fedyanin, Mikhail
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
BLOOMSI, NCT06414304: Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

Recruiting
N/A
70
RoW
OncoAtlas LLC, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer, Cancer, Colon Adenocarcinoma
07/25
07/26
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
Khokhlova, Svetlana
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tryakin, Alexey
CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting
3
355
RoW
Cetuximab, panitumumab
City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation
12/26
12/27
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
GENCONCOR-1, NCT06449989: Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Recruiting
N/A
30
RoW
Tumor samples will be tested for mutation status of KRAS, NRAS, BRAF, HER2 and MSI
Blokhin's Russian Cancer Research Center
Colorectal Cancer Metastatic, Brain Metastases, Adult, Ras (KRAS or NRAS) Gene Mutation, BRAF Gene Mutation, HER2 Gene Mutation, MSI
04/25
04/25
Ganshina, Inna
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
Fedyanin, Mikhail
UNIVERSE, NCT06640530: Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin

Recruiting
3
392
RoW
BCD-263, Nivolumab, Opdivo
Biocad
Advanced Melanoma, Melanoma (Skin)
12/25
03/27
OCTAVA, NCT05732805: A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Active, not recruiting
3
270
RoW
BCD-217, nurulimab+prolgolimab, BCD-100, prolgolimab, Forteca, Placebo
Biocad
Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
06/24
07/25
BLOOMSI, NCT06414304: Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy

Recruiting
N/A
70
RoW
OncoAtlas LLC, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka
Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer, Cancer, Colon Adenocarcinoma
07/25
07/26
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23
Khokhlova, Svetlana
DEFENDOR special, NCT04905329: A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations

Recruiting
N/A
285
RoW
Empegfilgrastim
Moscow Clinical Scientific Center
Solid Tumor, High-Risk Cancer, Breast Cancer, Gastrointestinal Cancer, Gynecological Malignancies, Myelosuppression
12/22
09/23

Download Options